

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-36. (Canceled)

37. (Previously presented) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:107.

38. (Original) A fusion protein comprising a polypeptide according to claim 37.

39. (Original) A composition comprising a polypeptide of claim 37 or a fusion protein of claim 38; and a physiologically acceptable carrier.

40. (Original) The composition of claim 39, further comprising a non-specific immune response enhancer.

41. (Original) The composition of claim 40, wherein the non-specific immune response enhancer is an adjuvant.

42-55. (Canceled)

56. (New) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:107 or an immunogenic fragment thereof, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length.

57. (New) A fusion protein comprising a polypeptide according to claim 56.

58. (New) A composition comprising a polypeptide of claim 56 or a fusion protein of claim 57; and a physiologically acceptable carrier.

59. (New) The composition of claim 58, further comprising a non-specific immune response enhancer.